Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial-Reference-Cited by-同舟云学术

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Published:2018-08 Issue:8 Volume:6 Page:605-617
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Tuttle Katherine R,Lakshmanan Mark C,Rayner Brian,Busch Robert S,Zimmermann Alan G,Woodward D Bradley,Botros Fady T

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease;KDOQI;Am J Kidney Dis,2007

2. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease;KDIGO;Kidney Int Suppl,2013

3. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies;Davies;Clin Pharmacol,2016

4. KDOQI clinical practice guideline for diabetes and CKD: 2012 update;National Kidney Foundation;Am J Kidney Dis,2012

5. Diabetic kidney disease: a report from an ADA consensus conference;Tuttle;Am J Kidney Dis,2014

Cited by 398 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis;Clinical Pharmacokinetics;2024-01-18

2. Diabetic Nephropathy;Textbook of Diabetes;2024-01-12

3. Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease;Diabetes, Obesity and Metabolism;2024-01-08

4. Glucagon-like Peptide-1 Agonists;JBJS Reviews;2024-01

5. Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes;Metabolism;2024-01